Nine more pharmaceutical manufacturers have signed most-favored-nation pricing agreements with the Trump administration, bringing the total to 26 companies covering what the White House says is 89 percent of the branded drug market. The announcement came from the Oval Office on August 31, 2026.
The nine are Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals and UCB. They join 17 larger manufacturers that signed earlier, among them Pfizer, Eli Lilly and Novo Nordisk. The White House describes the newcomers as mid-sized companies, and says the drugs covered treat conditions including hemophilia, Parkinson's disease, macular degeneration, glaucoma, liver disease, skin conditions and several cancers. The administration announced the first agreement with a manufacturer in the fall of 2025 and an earlier round of deals that December.
For most households, the direct effect on out-of-pocket costs is likely to be small or absent. The core commitment in these deals is to give every state Medicaid program access to most favored nation prices, meaning the lowest price the manufacturer charges in comparable wealthy countries. Medicaid enrollees already pay very little at the pharmacy counter, typically a few dollars per prescription, and federal law already requires manufacturers to give Medicaid substantial rebates.
Where the Savings Land
The savings in a Medicaid-focused deal flow to state and federal budgets rather than to a patient's wallet. The White House fact sheet frames the result as billions of dollars in savings and says the Council of Economic Advisers estimates total savings from all the most favored nation deals will reach $600 billion over the next decade.
That figure is an administration projection, not an audited result, and it covers ten years across all 26 agreements. It has not been independently scored by the Congressional Budget Office.
The agreements also commit the companies to guarantee most favored nation prices on new medicines they bring to market. That provision, if it holds, is where a broader effect on commercially insured patients could eventually appear, since launch prices for new drugs help set what insurers pay and what deductible phase patients absorb. Nothing in the announcement changes prices on drugs already on the market for people with employer coverage or Medicare.
Some households do have a direct path to lower cash prices. The administration launched the discount site in February, and TrumpRx now lists discounted cash prices on selected medicines. The White House says patients have saved more than $700 million through it since launch. The site does not accept insurance, so it functions as a cash pay alternative that may or may not beat a given plan's copay.
The Supply Chain Piece
A less discussed part of the deals involves stockpiling raw drug ingredients. The nine companies committed to invest at least $19.6 billion collectively in United States manufacturing in the near term, and several agreed to donate active pharmaceutical ingredients to the Strategic Active Pharmaceutical Ingredients Reserve.
The specific contributions are unusually concrete. UCB will contribute 163 tons of levetiracetam, an anti-seizure medicine. Sun Pharma will contribute 71.4 tons of clindamycin and 6.75 tons of doxycycline, both antibiotics. Teva will contribute 45 metric tons of metronidazole, which treats bacterial and parasitic infections, and 4.8 tons of amlodipine, a blood pressure drug. Astellas will contribute 25 kilograms of tacrolimus, an immunosuppressant used to prevent organ transplant rejection.
That list reads like a shortage list. Generic sterile injectables and older oral generics are the categories where American pharmacies have repeatedly run dry, and where manufacturing is concentrated in a small number of overseas plants. Whether a national ingredient reserve translates into fewer empty shelves depends on finished product manufacturing capacity, which the reserve does not by itself address.
The Questions Still Unanswered
Several questions have no answer yet. The agreements are voluntary and are not written into statute, which means a future administration could unwind them and companies could exit. President Trump has called on Congress to pass what the White House calls the Great Healthcare Plan, and any effort to codify most favored nation pricing would face the pharmaceutical industry's long-standing opposition.
The interaction with the existing Medicaid Drug Rebate Program is also unresolved. That program already guarantees Medicaid a statutory minimum rebate and additional rebates when prices rise faster than inflation. How a separately negotiated most favored nation price stacks on top of, or substitutes for, those rebates has not been spelled out publicly, and state Medicaid agencies will have to implement whatever the answer turns out to be.
Patient advocacy groups have made the same point. Patients For Affordable Drugs said the terms of the agreements, including how the prices will be implemented and enforced, have not been made public.
Practical Steps for Households This Week
For someone on Medicaid, nothing to do. Copays are set by state rules and are already nominal, and no action is required to receive whatever pricing the state negotiates.
For someone with commercial insurance or Medicare, the practical advice is unchanged by this announcement. Before filling an expensive prescription, it is worth comparing the plan copay against the cash price at a discount pharmacy program, checking whether a generic or therapeutic alternative exists, and asking the prescriber about manufacturer patient assistance programs, which are separate from any of these federal agreements. Patients facing a denial can ask about prior authorization and the plan's appeal process.
For patients on the specific drugs the nine companies make, including hemophilia factor products, Parkinson's medicines and eye drugs for glaucoma and macular degeneration, no supply change was announced, and no prescription needs to be adjusted. Anyone weighing a change to a treatment should raise it with the clinician managing the condition rather than acting on a pricing announcement.
The administration has not published a drug-by-drug list of which products from the nine companies are covered or when the new Medicaid prices take effect. Until that appears, the size of the effect on any individual medicine cannot be calculated.
Key Questions Answered
What was announced? Nine additional pharmaceutical manufacturers signed most favored nation pricing agreements, bringing the total to 26 companies.
Which companies? Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB.
Will my copay drop? Probably not because of this announcement. The agreements center on prices that state Medicaid programs pay, and Medicaid copays are already nominal.
Who actually saves money? State and federal Medicaid budgets in the near term. The administration projects $600 billion in savings over a decade across all the deals, a figure it has not had independently scored.
Does this affect Medicare or employer coverage? Not directly for existing drugs. The commitment to offer most favored nation prices on newly launched medicines could affect future prices more broadly.
What is the ingredient reserve about? Four companies agreed to donate bulk quantities of drugs including levetiracetam, clindamycin, doxycycline, metronidazole, amlodipine and tacrolimus to a national ingredient stockpile.
Are these agreements permanent? No. They are voluntary and not written into law. Codifying them would require Congress.
